Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 1/20 | 0.64 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.50 |
| ▸ | CPB1 | P15086 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9501043 | 0.99 | CCR6 (0.62) | CCR6PAX8HTTLMNASMN1; SMN2 | |
| SCHEMBL2075425 | 0.98 | CCR6 (0.60) | CCR6PAX8HTTLMNASMN1; SMN2 | |
| SCHEMBL411758 | 0.98 | CCR6 (0.60) | CCR6PAX8HTTLMNASMN1; SMN2 | |
| SCHEMBL415520 | 0.98 | CCR6 (0.64) | CCR6PAX8HTTLMNASMN1; SMN2 | |
| SCHEMBL2076254 | 0.96 | CCR6 (0.62) | CCR6PAX8HTTLMNASMN1; SMN2 | |
| SCHEMBL2076561 | 0.95 | CCR6 (0.60) | CCR6PAX8HTTLMNASMN1; SMN2 | |
| SCHEMBL417675 | 0.95 | CCR6 (0.60) | CCR6PAX8HTTLMNASMN1; SMN2 | |
| SCHEMBL4704081 | 0.94 | CCR6 (0.60) | CCR6PAX8HTTLMNASMN1; SMN2 | |
| SCHEMBL3760231 | 0.92 | CCR6 (0.57) | CCR6PAX8HTTLMNASMN1; SMN2 | |
| SCHEMBL17872132 | 0.91 | HTT (0.58) | CCR6PAX8HTTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | LUMIPHORE, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-8664409-B2 | Process for the preparation of (poly) aminoalkylaminoacetamide derivatives of epipodophyllotoxin useful for their applications in therapeutics as anticancer agent | PIERRE FABRE MEDICAMENT (FR) | 2014-03-04 | — | — | US | disclosed |
| US-20120022273-A1 | PROCESS FOR THE PREPARATION OF (POLY) AMINOALKYLAMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN USEFUL FOR THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-01-26 | — | — | US | disclosed |
| EP-0105193-B1 | SPERGUALIN-RELATED COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1988-08-24 | — | — | EP | disclosed |
| EP-0117501-B1 | A PROCESS FOR THE PREPARATION OF 1,5-DIPROTECTED-1,5,10-TRIAZADECANE, INTERMEDIATES THEREOF AND THEIR PREPARATION | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1988-04-06 | — | — | EP | disclosed |
| US-4529549-A | Compound containing guanidine and amino groups | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1985-07-16 | — | — | US | disclosed |
| EP-0117501-A1 | A process for the preparation of 1,5-diprotected-1,5,10-triazadecane, intermediates thereof and their preparation | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1984-09-05 | — | — | EP | disclosed |
| EP-0105193-A2 | Spergualin-related compounds, processes for the preparation thereof and their use as medicaments | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1984-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | CLTB, CLTA, EPCAM | CCR6 142/4885PAX8 4088/4885HTT 1559/4885 |
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | CLTB, CLTA, EPCAM | CCR6 142/4885PAX8 4088/4885HTT 1559/4885 |
| US-20120022273-A1 | PROCESS FOR THE PREPARATION OF (POLY) AMINOALKYLAMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN USEFUL FOR THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENT | PTMA, NPEPPS, DNPEP | CCR6 3824/4885PAX8 2180/4885HTT 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.